Ingelheim Am Rhein, Rheinland-Pfalz, Germany Boehringer Ingelheim Venture Fund appeared to be the VC, which was created in 1973. The main office of represented VC is situated in the Ingelheim Am Rhein. The company was established in Europe in Germany. Boehringer Ingelheim Venture Fund appeared to be a CVC structure as part of the corporation.
The overall number of key employees were 7.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Boehringer Ingelheim Venture Fund, startups are often financed by High-Tech Gru00fcnderfonds, Forbion Capital Partners, BioMedPartners. The meaningful sponsors for the fund in investment in the same round are BioMedPartners, Forbion Capital Partners, Takeda Ventures. In the next rounds fund is usually obtained by High-Tech Gru00fcnderfonds, Forbion Capital Partners, BioMedPartners.
Deals in the range of 10 - 50 millions dollars are the general things for fund. Considering the real fund results, this VC is 27 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2016. The higher amount of exits for fund were in 2019. The fund is constantly included in 2-6 investment rounds annually. Opposing the other organizations, this Boehringer Ingelheim Venture Fund works on 12 percentage points less the average amount of lead investments.
Among the most popular fund investment industries, there are Therapeutics, Robotics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Promethera Biosciences, Wellth, Tacalyx. The fund has no exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Shengbao Bio | 26 Jul 2024 | Shenzhen, Guangdong, China | |||
HepaRegeniX | $17M | 10 Jul 2024 | Ulm, Baden-Württemberg, Germany | ||
Asgard Therapeutics | $35M | 14 Mar 2024 | Lund, Skane Lan, Sweden | ||
Glox Therapeutics | $5M | 14 Nov 2023 | Glasgow City, Glasgow, United Kingdom | ||
Actym | $25M | 18 Oct 2023 | San Francisco, California, United States | ||
smartbax | $1M | 23 May 2023 | Munich, Bayern, Germany | ||
DiogenX | $39M | 10 May 2023 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
Rewind Therapeutics | 25 Jan 2023 | - | |||
Rgenta Therapeutics | $52M | 29 Nov 2022 | Cambridge, Massachusetts, United States |
– Dopavision, a Berlin, Germany-based company focused on development of digital therapeutics, raised €12M in Series A funding.
– The round was led by Seventure Partners with participation from Novartis Pharmaceuticals, Boehringer Ingelheim Venture Fund and Ababax Health.
– The new investment will be used for the clinical development of MyopiaX, its lead product in childhood myopia, activities to provide innovative digital treatments for children leveraging games, educational or cognitive training applications, and potentially broaden its pipeline to new indications.
– Delonix Bioworks has closed a $14m Series Seed financing to accelerate the development of its innovative synthetic vaccines.
– The financing was led by Boehringer Ingelheim Venture Fund and IDG Capital with participation from ZhenFund and an undisclosed investor.
– The financing will be used to accelerate the building of synthetic biology vaccine platforms and advance pipelines of synthetic vaccines to clinical trials.
– Delonix is working on innovative synthetic biology approaches to develop the next generation medical solutions to address global public health challenges.
– Current lead programs target anti-microbial resistance (AMR).
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Shengbao Bio | 26 Jul 2024 | Shenzhen, Guangdong, China | |||
HepaRegeniX | $17M | 10 Jul 2024 | Ulm, Baden-Württemberg, Germany | ||
Asgard Therapeutics | $35M | 14 Mar 2024 | Lund, Skane Lan, Sweden | ||
Glox Therapeutics | $5M | 14 Nov 2023 | Glasgow City, Glasgow, United Kingdom | ||
Actym | $25M | 18 Oct 2023 | San Francisco, California, United States | ||
smartbax | $1M | 23 May 2023 | Munich, Bayern, Germany | ||
DiogenX | $39M | 10 May 2023 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
Rewind Therapeutics | 25 Jan 2023 | - | |||
Rgenta Therapeutics | $52M | 29 Nov 2022 | Cambridge, Massachusetts, United States |
